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Introduction
The peritoneal cavity is the second most common location
for the development of isolated metastases of colorectal
origin1,2. Peritoneal metastatic disease was once consid-
ered an end-stage disease with a poor median survival of
several months after palliative treatment3–5. However, sur-
vival rates have improved since the introduction of cytore-
ductive surgery (CRS) with hyperthermic intraperitoneal
chemotherapy (HIPEC). Numerous studies have identified
the peritoneal carcinomatosis index (PCI), a measure of the
extent of peritoneal disease, and completeness of CRS as
important prognostic factors for oncological outcome6–10.
However, identification of peritoneal lesions, especially in
diffuse miliary disease, and discriminating between benign
fibrosis (common after surgery and neoadjuvant therapy)
and malignant lesions can be challenging. Therefore, a
reliable method for identifying (small) peritoneal tumour
deposits could be of great importance to achieving com-
plete CRS.
Near-infrared (NIR) fluorescence imaging techniques
using tumour-targeting tracers may aid in this respect. In
recent years, fluorescence-guided surgery has gained inter-
est, and has been able to provide surgeons with real-time
feedback and visualization of malignant tissues11–14.
SGM-101, a carcinoembryonic antigen (CEA)-specific
tumour-targeted fluorescent agent, can be used for fluo-
rescence imaging to identify malignant tissue of colorectal
origin. The fact that CEA is overexpressed in more than
90 per cent of all colorectal cancer cells, with limited
expression in benign tissue, makes it an ideal target for
fluorescence imaging of colorectal neoplastic lesions15–17.
The aims of this study were to evaluate the effectiveness of
fluorescence imaging with SGM-101 for the detection of
peritoneal metastases of colorectal origin and the potential
influence on intraoperative decision-making. The main
objective was to distinguish whether the PCI, and thus
the completeness of cytoreduction, can be changed with
SGM-101 and fluorescence imaging.
Methods
An exploratory, multicentre pilot study was performed
in patients with peritoneal metastatic colorectal cancer.
Patients were scheduled for CRS-HIPEC, and SGM-101
was administered intravenously 4–6 days before surgery.
During surgery, a clinical PCI was determined using
standard tactile and visual feedback. Subsequently, a
fluorescence-based peritoneal carcinomatosis index (fPCI)
was determined using the Quest Spectrum® fluorescence
camera system (Quest Medical Imaging, Middenmeer, the
Netherlands), an imaging system dedicated to fluorescence
imaging in the 700-nm NIR spectrum. Both clinically
suspected malignant and fluorescent lesions were resected
and assessed by the pathologist. Changes in the PCI and
surgical plan, and the concordance between clinical detec-
tion and fluorescence imaging were correlated with the
histopathological analysis. Details of the methods can be
found in Appendix S1 (supporting information).
Results
Between January 2017 and January 2019, 14 patients
diagnosed with peritoneal metastases of colorectal origin
were included in this study. The clinical characteristics
and PCI outcomes are summarized in Tables S1 and S2
respectively (supporting information). Of the 14 patients,
six were diagnosed with a locally advanced or recurrent
rectal tumour with peritoneal metastases, and received
neoadjuvant treatment consisting of either induction
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Fig. 1 Ex vivo fluorescence imaging of a lesion in the omentum
a  White light b  Near-infrared fluorescence c  Merged
Ex vivo a white light, b near-infrared (NIR) fluorescence and c merged white light and NIR fluorescence images of a lesion in the omentum detected in
vivo, which was not suspicious clinically, resulting in a change in peritoneal carcinomatosis index from 4 to 6. Histopathological examination confirmed
that this lesion was malignant.
chemotherapy followed by chemoradiotherapy (CRT) or
CRT alone. Nine patients presented with synchronous and
five with metachronous peritoneal metastases. SGM-101
was well tolerated in all patients; no allergic or anaphy-
lactic reactions were reported during or after SGM-101
administration. CRS-HIPEC was executed successfully in
12 of the 14 patients. Only an exploratory laparotomy was
performed in two patients, as the disease was too extensive
and unresectable. However, for clinical purposes, clinical
and fluorescence-based PCI inspections were performed,
and biopsies were taken that were also investigated for
fluorescence signal.
Median clinical PCI was 7 (2–39) and median fPCI
was 6.5 (2–39). The PCI changed owing to fluorescence
imaging in seven patients. In six of these patients, the fPCI
was higher than the clinical PCI, which was accurate in
four patients, as confirmed by histopathological analysis.
One patient had a PCI increase from 10 to 11 owing to
a fluorescent lesion on the mesentery of the proximal
ileum, which was not considered malignant on traditional
inspection or palpation. The second patient had multiple
additional lesions in the omentum that were not identified
by standard visual techniques, but only by fluorescence
imaging, increasing the PCI from 4 to 6 (Fig. 1). In the
third and fourth patients, fluorescent positive lesions on
the left upper peritoneum and peritoneum of the bladder
increased the PCI from 9 to 10 and from 2 to 4 respectively.
Both lesions were visible, but not considered malignant
on initial inspection and palpation. In two patients, the
PCI change due to fluorescence imaging was incorrect. A
false-positive lesion on the liver capsule, detected by flu-
orescence imaging, led to an incorrect PCI increase from
4 to 5 and unnecessary resection of a superficial lesion
on the liver capsule. The other patient, who received
neoadjuvant chemotherapy according to the CAIRO-6
trial protocol, had a complete response. Six lesions were
resected, which were all clinically suspect for malignancy;
five of these lesions were fluorescent. Histopathological
analysis confirmed that all lesions were benign, containing
collagen-rich connective tissue, hypervascularization and
an inflammatory reaction. One patient had a decrease
in PCI owing to fluorescence imaging. This patient had
a PCI of 5 and a fPCI of 4; however, after histopatho-
logical analysis the PCI was 3. Fluorescence imaging
correctly identified two lesions (mesentery of the upper
and lower ileum) as benign, but a false-positive lesion in
the omentum eventually led to an incorrect fPCI. Both
lesions on the mesentery of the ileum were still resected
as they were clinically suspicious; bowel resection was not
included.
Table 1 Performance of fluorescence imaging for detection of lesions
Malignant Benign Total Sensitivity (%) Speciﬁcity (%) PPV (%) NPV (%) Accuracy (%)
Fluorescence positive 65 (TP) 14 (FP) 79
Fluorescence negative 1 (FN) 23 (TN) 24
Total 66 37 103 98.5 (65 of 66) 62.2 (23 of 37) 82.3 (65 of 79) 95.8 (23 of 24) 85.4 (88 of 103)
TP, true positive; FP, false positive; FN, false negative; TN, true negative; PPV, positive predictive value; NPV, negative predictive value.
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Fluorescence imaging in peritoneal metastasized colorectal cancer
A total of 103 lesions were excised from the 14 patients.
Histopathology revealed that 66 of these lesions were
malignant and 37 were benign. Of the 103 lesions, 79 were
identified with fluorescence. Sixty-five of the 66 malignant
lesions were fluorescent (true positive), resulting in a sen-
sitivity of 98.5 per cent. No fluorescence was observed in
23 of the 37 benign lesions (true negative), resulting in
a specificity of 62.2 per cent. This led to an accuracy of
fluorescence imaging of 85.4 per cent. Nevertheless, 14
lesions showed a false-positive signal and one lesion was
false negative, resulting in a positive predictive value of 82.3
per cent and a negative predictive value of 95.8 per cent
(Table 1).
Discussion
SGM-101 had a high negative predictive value of 95.8
per cent and an accuracy of 85.4 per cent, which is in
accordance with previous and concurrent studies with
SGM-101, emphasizing that this technique is consis-
tently reliable13. The selection of patients with peritoneal
metastases of colorectal origin who might benefit from
CRS-HIPEC is a major challenge. Several studies7,8,18,19
have demonstrated that the extent of peritoneal disease,
best measured with the PCI, is one of the most impor-
tant prognostic factors for increased local and distant
recurrence rates and diminished survival. Completeness
of cytoreductive surgery is another important prognostic
factor for improved oncological outcomes9,10,20. In a ret-
rospective analysis of 523 patients, Elias and colleagues6
showed that, besides lymph node status, surgical experi-
ence and adjuvant chemotherapy, PCI and the completion
of cytoreduction were independent prognostic factors for
disease-free survival. With this in mind, it is apparent that
adequate detection of peritoneal deposits is key to deter-
mining whether CRS-HIPEC is feasible and improves the
completeness of cytoreduction. Even though a change in
PCI might not fully reflect the benefit of tumour deposit
detection with fluorescence imaging, because the addi-
tional information about, for example, an extra lesion,
might not alter the PCI, it is still beneficial for a more
complete cytoreduction. The fact that this technique was
able to detect additional lesions that were not considered
to be malignant based on standard visual and tactile feed-
back is of great importance. The PCI increased accurately
based on fluorescence imaging in almost one-third of
the patients, which led to resection of lesions that would
otherwise have been left behind. These results demon-
strate the potential benefit of CEA-specific fluorescence
imaging, as the detection of additional lesions with the
help of this technique might result in more complete
cytoreduction and subsequently improved oncological
outcomes.
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